Clinic
HH Killeen Health System LLC
HH Killeen Health System LLC was paid $6.95M by Medicaid between Jul 2020 and Dec 2024, across 78 billing codes. Its largest line is 99284, emergency room visit (serious) — 44% of everything it billed.
33Billing provider infoHH KILLEEN HEALTH SYSTEM LLC
HARKER HEIGHTS, TX 76548
HARKER HEIGHTS, TX 76548
33aNPI1841562709assigned 02/07/2012
33bProvider typePhysical Therapy Clinic/Center
28Total paid$6.95M
24GClaims87,194
24DCodes billed78
24AFirst – last monthJul 2020 – Dec 2024
Compared with peers
Next to other Physical Therapy Clinic/Center providers in Texas
Rank by total paid#1 of 32
Median peer was paid$23K
This provider vs. median298×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,286 | $190K | |
| 2021 | 25,893 | $1.91M | |
| 2022 | 29,074 | $2.32M | |
| 2023 | 19,801 | $1.81M | |
| 2024incomplete | 10,140 | $725K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 44% | 10,878 | 10,220 | $3.06M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 25% | 15,015 | 14,400 | $1.72M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 3,242 | 2,990 | $945K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.1% | 11,017 | 9,901 | $351K |
| 86703 | 2.5% | 998 | 940 | $172K | |
| 80053 | Comprehensive metabolic panel | 1.6% | 8,794 | 7,989 | $108K |
| 87428 | <1% | 2,960 | 2,831 | $57K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,442 | 1,319 | $51K |
| 86592 | <1% | 1,054 | 978 | $45K | |
| 59025 | Fetal non-stress test | <1% | 308 | 265 | $33K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,896 | 1,642 | $32K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 170 | 145 | $31K |
66 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 150 | $29K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 150 | $27K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,699 | $25K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,157 | $24K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 141 | $22K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 169 | $20K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 733 | $17K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 60 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,691 | $13K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 107 | $12K |
| 81025 | <1% | 1,574 | $10K | |
| 81001 | <1% | 2,668 | $9K | |
| 93976 | <1% | 91 | $8K | |
| 86762 | <1% | 141 | $7K | |
| 86803 | <1% | 52 | $7K | |
| 84484 | <1% | 1,086 | $7K | |
| 87340 | <1% | 98 | $7K | |
| 82950 | <1% | 125 | $6K | |
| 87081 | <1% | 89 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 82 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 706 | $6K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 280 | $6K |
| 86900 | <1% | 194 | $5K | |
| 86787 | <1% | 77 | $5K | |
| 86850 | <1% | 52 | $5K | |
| 86901 | <1% | 195 | $4K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 82 | $4K |
| 76801 | <1% | 43 | $4K | |
| 0002A | <1% | 153 | $3K | |
| 83690 | <1% | 691 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,718 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 264 | $3K |
| 83021 | <1% | 25 | $3K | |
| 0001A | <1% | 168 | $2K | |
| 84702 | <1% | 244 | $2K | |
| 80061 | Lipid panel | <1% | 126 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 84 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 115 | $1K |
| 81003 | <1% | 994 | $1K | |
| 82105 | <1% | 13 | $1K | |
| 83735 | <1% | 430 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 676 | $856.18 |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12 | $824.06 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 365 | $807.29 |
| 87210 | <1% | 32 | $534.10 | |
| 82553 | <1% | 43 | $277.09 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 69 | $260.19 |
| 83880 | <1% | 49 | $224.41 | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17 | $219.20 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 44 | $218.80 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 58 | $208.22 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 31 | $194.01 |
| 82550 | <1% | 72 | $183.33 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31 | $179.16 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 498 | $127.39 |
| 84703 | <1% | 13 | $89.31 | |
| 83605 | <1% | 44 | $67.58 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 15 | $45.02 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 203 | $28.76 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14 | $24.70 |
| 82962 | <1% | 182 | $8.69 | |
| J2704 | Injection, propofol, 10 mg | <1% | 116 | $1.56 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 80 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 13 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 13 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDIETZE, ZACH (CEO)